Last updated: September 14, 2026
Teprotumumab-trbw, marketed as Tepezza by Amgen, is the only FDA-approved therapy specifically indicated for thyroid eye disease (TED). Its commercial value is driven by high treatment cost, limited approved competition, and expansion beyond highly active disease. U.S. sales increased rapidly after launch, reaching roughly $2 billion annually under Horizon Therapeutics before moderating after Amgen’s acquisition. The principal risks are reimbursement controls, diagnosis and referral constraints, safety monitoring, treatment-center capacity, and future competition from IGF-1R antibodies with shorter or subcutaneous dosing.
What is the FDA status of teprotumumab-trbw?
The FDA approved Tepezza on January 21, 2020, for the treatment of TED in adults. Teprotumumab is a fully human monoclonal antibody that inhibits the insulin-like growth factor 1 receptor, or IGF-1R, a target implicated in the pathophysiology of TED.
| Attribute |
Detail |
| Brand |
Tepezza |
| Active ingredient |
Teprotumumab-trbw |
| Sponsor at launch |
Horizon Therapeutics |
| Current owner |
Amgen |
| FDA application |
Biologics license application |
| Initial approval |
January 21, 2020 |
| Indication |
Thyroid eye disease in adults |
| Administration |
Intravenous infusion |
| Standard regimen |
Initial 10 mg/kg dose, followed by 20 mg/kg every three weeks for seven additional doses |
| Typical course |
Eight infusions over approximately 21 weeks |
| FDA pathway |
Biologic license, not an abbreviated new drug application |
The standard course consists of eight infusions. Treatment is administered in physician offices, infusion centers, or hospital outpatient settings. Product acquisition, preparation, infusion administration, and payer approval create a more complex commercial pathway than for an oral specialty drug.
How large is the teprotumumab-trbw market?
The addressable U.S. TED market is substantially larger than the treated population. TED is associated with Graves’ disease, but diagnosis is frequently delayed and patients are managed across endocrinology, ophthalmology, oculoplastic surgery, and primary care.
Commercial demand has been shaped by three factors:
- The absence of another FDA-approved TED-specific medicine.
- Use in patients with active and, following label expansion, longer-duration disease.
- Greater recognition of TED as a disease requiring treatment rather than only surgery, corticosteroids, or observation.
The market remains concentrated in the United States. International opportunity is constrained by regulatory approvals, reimbursement, infusion infrastructure, and differences in TED diagnosis.
What is the treatment cost of Tepezza?
Tepezza has an annualized course cost generally estimated in the low-to-mid six figures before discounts, payer rebates, and provider economics. The actual amount depends on body weight, vial utilization, site of care, reimbursement contracts, and whether treatment is interrupted.
The high price produces significant revenue per treated patient but also increases payer scrutiny. Prior authorization commonly requires documentation of diagnosis, disease severity, prior treatment, and appropriate administration. Commercial growth therefore depends on both patient identification and approval conversion.
What is the financial trajectory of teprotumumab-trbw?
Tepezza became Horizon’s largest commercial product within its first full year. Public company filings reported the following approximate net sales:
| Year |
Approximate Tepezza net sales |
Commercial context |
| 2020 |
$0.4 billion |
Partial first year after launch |
| 2021 |
$1.7 billion |
Rapid physician adoption |
| 2022 |
$2.0 billion |
Peak Horizon-era growth |
| 2023 |
Approximately $1.9 billion |
Transition to Amgen ownership and demand normalization |
| 2024 |
Approximately $1.8 billion to $2.0 billion |
Mature specialty-product performance |
The 2020 and 2021 figures reflect the rapid conversion of a previously untreated specialty market. Growth moderated after 2022 as the highest-propensity patients entered treatment, payers tightened utilization management, and physicians gained more experience with the product’s safety profile.
Why did Tepezza sales grow so quickly?
Tepezza combined a large unmet need with regulatory exclusivity and a high per-patient treatment value. Before approval, TED treatment relied on systemic corticosteroids, immunosuppressants, orbital radiation, surgery, and observation. These options did not provide an equivalent FDA-approved pharmacologic treatment across the disease spectrum.
Horizon also invested in disease education, specialist outreach, patient-support services, and payer access. Those activities improved referral and treatment-center capacity, although they did not remove the underlying diagnostic bottleneck.
What did the Amgen acquisition change?
Amgen completed its acquisition of Horizon in October 2023 for approximately $27.8 billion, including assumed debt. Tepezza became one of Amgen’s largest growth products and an important contributor to the acquired portfolio.
Amgen’s ownership created commercial advantages in global regulatory operations, medical affairs, manufacturing, and payer contracting. It also placed Tepezza within a larger inflammation and immunology portfolio. The transaction increased the strategic value of protecting Tepezza revenue through the end of biologic exclusivity and through lifecycle management.
When does teprotumumab-trbw lose exclusivity?
Tepezza has several layers of exclusivity, and no single date determines all competitive entry.
Regulatory exclusivity
The reference biologic received FDA approval in January 2020. Under the Public Health Service Act, a biosimilar application generally cannot be approved until 12 years after first licensure of the reference biologic, subject to statutory provisions and litigation timing. That places the principal U.S. biosimilar approval barrier near January 2032.
Tepezza also received orphan-drug designation. Orphan-drug exclusivity generally lasts seven years from approval, placing the core orphan period near January 2027. Orphan exclusivity and biologic reference-product exclusivity operate under different legal frameworks and should not be treated as interchangeable.
| Protection |
Approximate end date |
Business implication |
| Seven-year orphan exclusivity |
January 2027 |
Limits approval of the same drug for the same orphan indication |
| Twelve-year biologic reference exclusivity |
January 2032 |
Limits FDA approval of a biosimilar reference-product pathway |
| Patent protection |
Patent-specific |
May extend beyond statutory exclusivity |
What patents protect Tepezza?
Teprotumumab is a biologic, so its competitive protection is divided between patent rights, FDA exclusivity, trade secrets, manufacturing know-how, and regulatory barriers.
Biologics are not listed in the FDA Orange Book in the same manner as small-molecule drugs. Biosimilar-related regulatory information is maintained through the FDA’s Purple Book framework. This distinction matters because a Tepezza competitive challenge would not follow the ordinary small-molecule Paragraph IV process used for an ANDA.
Potentially relevant patent categories include:
- Antibodies targeting IGF-1R.
- Teprotumumab or closely related antibody sequences.
- Methods of treating thyroid eye disease.
- Dosing schedules and patient-selection methods.
- Cell-line, purification, and manufacturing processes.
- Formulation and stability technologies.
The practical protection profile is therefore broader than a single composition-of-matter patent. Patent expiry dates must be assessed claim by claim, including terminal disclaimers, patent-term adjustment, patent-term extension, and claim scope. A biosimilar sponsor may challenge patents under the Biologics Price Competition and Innovation Act rather than through an ANDA Paragraph IV filing.
Are there Paragraph IV challenges to Tepezza?
No conventional Paragraph IV challenge is expected because Tepezza is licensed as a biologic rather than approved through a new drug application. A biosimilar sponsor would use the BPCIA patent-exchange and patent-litigation framework.
Publicly disclosed commercial risk has centered more on future biosimilar development and competing IGF-1R antibodies than on a mature wave of ANDA litigation. The earliest commercially meaningful biosimilar pressure is more likely to develop around the statutory biologic exclusivity window, unless a competitor secures an alternative approval route or successfully contests relevant patents earlier.
What is the biosimilar risk for teprotumumab-trbw?
Biosimilar risk is currently lower than generic risk for a small molecule because:
- Teprotumumab is a complex monoclonal antibody.
- Clinical development requires analytical, pharmacokinetic, immunogenicity, and often clinical evidence.
- Manufacturing capacity is difficult to replicate.
- The reference product has a concentrated specialist market.
- Payers may initially favor the branded product if switching creates clinical or operational friction.
Risk increases after 2032 as the reference-product exclusivity period expires. The commercial impact will depend on the number of biosimilar entrants, interchangeability designations, contracting strategy, and whether Amgen uses discounts or rebates to defend share.
Which companies are challenging Tepezza commercially?
The most important competitive threats are other IGF-1R-directed medicines and alternative immunomodulators.
| Competitor class |
Examples |
Competitive relevance |
| IGF-1R antibodies |
Veligrotug and other investigational agents |
Direct mechanism competition; potential shorter or subcutaneous regimens |
| Corticosteroids |
Oral or intravenous steroids |
Established, lower-cost, but less disease-specific |
| Immunomodulators |
Tocilizumab, rituximab and others |
Off-label use in selected patients |
| Surgery |
Orbital decompression, strabismus surgery, eyelid surgery |
Addresses structural consequences rather than replacing medical therapy |
| Radiation |
Orbital radiation |
Used in selected patients, with variable adoption |
Veligrotug has been a notable investigational competitor because it targets the same biological pathway and has been developed with the potential for a more convenient dosing profile. A product with comparable efficacy and less burdensome administration could pressure Tepezza’s share even before biosimilars arrive.
What formulation and administration advantages does Tepezza have?
Tepezza’s principal commercial limitation is intravenous administration. The eight-dose regimen requires repeated appointments, infusion capacity, weight-based dosing, and monitoring for adverse events.
Potential competitive advantages for a future product include:
- Subcutaneous administration.
- Fewer doses.
- Fixed dosing.
- Shorter infusion time.
- Lower infusion-center dependence.
- Easier treatment in community settings.
Tepezza’s established safety database, physician familiarity, and reimbursement infrastructure partly offset its administration burden. Formulation and delivery patents for competing products may therefore have commercial value even when the underlying target is the same.
What safety issues affect Tepezza demand?
The FDA label identifies risks including muscle spasms, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, and infusion-related reactions. In patients with pre-existing diabetes or glucose intolerance, hyperglycemia management can affect treatment decisions. Hearing-related adverse events have received particular attention because some patients report persistent or incompletely reversible hearing impairment.
Safety monitoring can reduce treatment initiation, increase discontinuation, and raise payer requirements. It also creates an opportunity for competitors that demonstrate comparable efficacy with improved tolerability or more convenient monitoring.
What is the generic launch scenario for Tepezza?
There is no conventional generic launch scenario. The relevant sequence is:
- Investigational competitors establish efficacy and safety.
- A biosimilar developer pursues the BPCIA pathway.
- Patent and regulatory exclusivity barriers are evaluated.
- FDA approval and any interchangeability determination are obtained.
- Payers decide whether to mandate substitution or prefer a lower-net-cost product.
- Amgen responds through contracting, patient services, dosing research, and lifecycle management.
The earliest high-impact erosion is more likely to come from a clinically differentiated competitor than from a biosimilar. A competing IGF-1R antibody that reduces infusion burden could affect new-patient starts, while biosimilars would primarily pressure net price after regulatory and patent barriers decline.
How strong is the Tepezza patent estate?
Tepezza’s commercial protection is strong through the combination of orphan exclusivity, biologic reference-product exclusivity, specialist adoption, manufacturing complexity, and the absence of an approved direct competitor. Patent strength is more difficult to evaluate from the product label alone because biologic protection may involve multiple families covering antibody sequences, uses, dosing, formulations, and manufacturing.
The estate is strongest where claims cover the specific antibody and commercially important TED treatment methods. Method-of-use claims can face validity and infringement challenges if competitors design around patient population, disease activity, dosing, or treatment sequence limitations.
Key Takeaways
- Teprotumumab-trbw is the only FDA-approved TED-specific therapy.
- Tepezza generated rapid sales growth, reaching approximately $2 billion annually during Horizon’s ownership.
- Amgen acquired Horizon in 2023 and now controls Tepezza commercialization and lifecycle strategy.
- Orphan exclusivity likely runs through approximately January 2027.
- Biologic reference-product exclusivity generally creates a major biosimilar barrier until approximately January 2032.
- A Paragraph IV ANDA challenge is not the relevant pathway; biosimilar competition would proceed under the BPCIA framework.
- The largest near-term threat is a competing IGF-1R therapy with better dosing convenience or tolerability.
- Revenue growth is constrained by diagnosis, infusion capacity, payer controls, and adverse-event monitoring.
- Patent protection must be assessed across antibody, method-of-use, formulation, and manufacturing claims rather than through the Orange Book alone.
FAQs
What is the annual revenue of Tepezza?
Tepezza generated roughly $2 billion in annual net sales at its commercial peak, with subsequent results generally in the approximately $1.8 billion-to-$2.0 billion range.
Is teprotumumab-trbw a biosimilar?
No. Teprotumumab-trbw is the active ingredient in the reference biologic Tepezza. A future biosimilar would need to demonstrate high similarity to the reference product.
Is Tepezza covered by Medicare?
Coverage depends on the treatment setting, Medicare benefit category, medical-necessity criteria, and payer policy. Physician-administered infusion may be reimbursed under medical-benefit rules rather than the traditional pharmacy benefit.
Can Tepezza be used after thyroid eye disease becomes inactive?
The FDA label covers adults with TED, and clinical use has expanded beyond narrowly defined active disease. Treatment decisions remain dependent on disease characteristics, risks, payer criteria, and physician judgment.
What could reduce Tepezza revenue before biosimilars launch?
The main factors are competing IGF-1R antibodies, lower-cost off-label immunomodulators, payer restrictions, reduced diagnosis or referral rates, safety concerns, and treatment regimens that reduce the need for repeated infusions.
References
- Amgen Inc. (2024). 2023 annual report.
- Amgen Inc. (2025). 2024 annual report.
- Food and Drug Administration. (2020). FDA approves first drug for thyroid eye disease.
- Food and Drug Administration. (2023). Tepezza prescribing information.
- Food and Drug Administration. (2024). Purple Book: Lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations.
- Horizon Therapeutics plc. (2023). 2022 annual report.
- U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Public Law 111-148.
